On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending ...

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why BIIB stock is a hold.

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...

Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) is conducting a Phase 3 ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Biogen Inc. closed 34.53% below its 52-week high of $207.59, which the company achieved on August 21st.

Biogen CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances the company's characteristic risky bets with a frank commitment to pragmatism.

Biogen agreed to buy Reata Pharmaceuticals for $7.3 billion, offering the company access to a drug that fits perfectly with its goals of treating both neuromuscular and rare diseases.